Tectonic Therapeutic (TECX) Competitors $46.79 -0.24 (-0.51%) (As of 05:27 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TECX vs. GMTX, SWTX, BHC, VERA, KYMR, CPRX, HCM, ARWR, DYN, and PTGXShould you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include Gemini Therapeutics (GMTX), SpringWorks Therapeutics (SWTX), Bausch Health Companies (BHC), Vera Therapeutics (VERA), Kymera Therapeutics (KYMR), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Dyne Therapeutics (DYN), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Tectonic Therapeutic vs. Gemini Therapeutics SpringWorks Therapeutics Bausch Health Companies Vera Therapeutics Kymera Therapeutics Catalyst Pharmaceuticals HUTCHMED Arrowhead Pharmaceuticals Dyne Therapeutics Protagonist Therapeutics Gemini Therapeutics (NASDAQ:GMTX) and Tectonic Therapeutic (NASDAQ:TECX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings. Does the media prefer GMTX or TECX? In the previous week, Tectonic Therapeutic had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Tectonic Therapeutic and 0 mentions for Gemini Therapeutics. Tectonic Therapeutic's average media sentiment score of 0.30 beat Gemini Therapeutics' score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral Tectonic Therapeutic Neutral Which has preferable valuation & earnings, GMTX or TECX? Gemini Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-64.12Tectonic TherapeuticN/AN/A$12.16M-$5.89-7.94 Is GMTX or TECX more profitable? Tectonic Therapeutic's return on equity of -35.53% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Tectonic Therapeutic N/A -35.53%-31.97% Do insiders and institutionals hold more shares of GMTX or TECX? 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, GMTX or TECX? Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500. Do analysts prefer GMTX or TECX? Tectonic Therapeutic has a consensus price target of $72.25, indicating a potential upside of 54.45%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the MarketBeat Community prefer GMTX or TECX? Gemini Therapeutics received 12 more outperform votes than Tectonic Therapeutic when rated by MarketBeat users. However, 100.00% of users gave Tectonic Therapeutic an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformGemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% Tectonic TherapeuticOutperform Votes7100.00% Underperform VotesNo Votes SummaryTectonic Therapeutic beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks. Ad Insiders ExposedNo one’s talking about these Trump tradesAs you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Tectonic Therapeutic News Delivered to You Automatically Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECX vs. The Competition Export to ExcelMetricTectonic TherapeuticBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$690.15M$2.93B$5.15B$9.00BDividend YieldN/A1.89%4.96%4.20%P/E Ratio-7.9445.2786.9916.99Price / SalesN/A397.971,132.84118.37Price / CashN/A174.7443.2737.84Price / Book21.963.934.804.90Net Income$12.16M-$42.00M$120.16M$225.21M7 Day Performance-1.64%0.20%0.72%3.16%1 Month Performance-6.03%-5.39%15.78%1.84%1 Year PerformanceN/A13.01%28.08%16.29% Tectonic Therapeutic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECXTectonic Therapeutic2.5673 of 5 stars$46.79-0.5%$72.25+54.4%N/A$690.29MN/A-7.94120GMTXGemini TherapeuticsN/A$64.50+2.5%N/A+12.5%$2.79BN/A-64.5030High Trading VolumeSWTXSpringWorks Therapeutics1.85 of 5 stars$37.37+5.0%$69.50+86.0%-0.4%$2.78B$135.49M-9.63305Positive NewsBHCBausch Health Companies3.1259 of 5 stars$7.48+0.1%$7.75+3.6%-4.7%$2.71B$9.47B-15.5820,270Short Interest ↓VERAVera Therapeutics3.3907 of 5 stars$42.31-0.7%$59.22+40.0%+169.2%$2.68BN/A-16.2140Positive NewsKYMRKymera Therapeutics2.0589 of 5 stars$40.79+0.3%$53.88+32.1%+57.5%$2.64B$87.56M-17.43170Analyst ForecastCPRXCatalyst Pharmaceuticals4.8839 of 5 stars$21.60+1.6%$31.14+44.2%+27.7%$2.58B$460.48M18.31167Positive NewsHCMHUTCHMED3.1781 of 5 stars$14.25-0.4%$19.00+33.3%-21.2%$2.48B$420.26M0.001,988Short Interest ↓News CoveragePositive NewsARWRArrowhead Pharmaceuticals4.497 of 5 stars$19.75+1.5%$42.70+116.2%-38.0%$2.46B$3.55M-3.93400DYNDyne Therapeutics3.0978 of 5 stars$23.91-0.3%$50.42+110.9%+78.3%$2.43BN/A-6.72100Positive NewsPTGXProtagonist Therapeutics2.8763 of 5 stars$40.60-2.1%$53.78+32.5%+69.9%$2.42B$323.80M15.26125Positive News Related Companies and Tools Related Companies Gemini Therapeutics Competitors SpringWorks Therapeutics Competitors Bausch Health Companies Competitors Vera Therapeutics Competitors Kymera Therapeutics Competitors Catalyst Pharmaceuticals Competitors HUTCHMED Competitors Arrowhead Pharmaceuticals Competitors Dyne Therapeutics Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TECX) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
